María Susana Juárez-Tobías
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Susana Juárez-Tobías has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Ernesto Noyola
Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autonoma de San Luis Potosi, San Luis Potosi 78210, Mexico
7 shared publications - Rosa María Wong-Chew
Infectious Diseases Research Laboratory, Research Division, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
7 shared publications - Fabian Rojas-Larios
Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
6 shared publications - María del Carmen Espinosa-Sotero
Department of Pediatrics, Hospital General de México Dr. Eduardo Liceaga, Mexico City 06760, Mexico
6 shared publications - Patricia Bautista-Carbajal
Infectious Diseases Research Laboratory, Research Division, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
6 shared publications - Miguel Leonardo García-León
Infectious Diseases Research Laboratory, Research Division, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
5 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Infection and mortality among children with cancer in Latin America and Spain: an observational cohort analysis
Background: Children with cancer in low-resource and resource-variable settings experience frequent infectious complications that precipitate clinical deterioration events (CDEs) and contribute substantially to mortality. We assessed the association between suspected and laboratory-confirmed infection and mortality during CDEs. Methods: We conducted a secondary analysis of a prospective CDE registry (April 2019–December 2024) across 80 hospitals in Latin America and Spain. CDEs were defined as unplanned ICU transfer or delivery of ICU-level interventions on the ward. Events were classified as suspected or not suspected to be caused by infection; suspected infections were further categorized into those with and without laboratory confirmation. We compared patient-, event-, and hospital-level characteristics across groups. The primary outcome was CDE mortality. Mortality risk was analyzed using generalized estimating equations (Poisson, log link) with hospital clustering, adjusted for C-reactive protein, neutropenia severity, cancer type, and relapse/progression. Results: Among 3,859 CDEs, infection was suspected as the cause of 2,873 (74.4%); of these, 1,296 (45.1%) had laboratory confirmation. Compared with no suspected infection, events with any suspected infection (confirmed or unconfirmed) was associated with higher mortality risk (aRR: 1.18; 95% CI: 1.02–1.37; p<0.05). Laboratory-confirmed infection further increased mortality risk (aRR: 1.30; 95% CI: 1.12–1.52; p=0.001). Bacteremia (aRR: 1.33, 95% CI: 1.15-1.54, p<0.001), fungemia (aRR: 1.54, 95% CI: 1.27-1.87, p<0.001), systemic viral (aRR: 1.52, 95% CI: 1.19-1.94, p=0.001), and polymicrobial bloodstream infections (aRR: 1.59, 95% CI: 1.31-1.94, p<0.001) independently increased mortality risk. Among children with suspected and laboratory-confirmed infections, those at publicly funded hospitals and in lower-middle and upper-middle income countries had higher mortality risk. Conclusions: Most CDEs in pediatric oncology were infection-related and confirmed infections substantially increased mortality risk. Strengthening infection prevention, early recognition, diagnostics, and timely treatment is critical to improving survival.
- 13 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Open AccessInfection and mortality among children with cancer in Latin America and Spain: an observational cohort analysis
Background: Children with cancer in low-resource and resource-variable settings experience frequent infectious complications that precipitate clinical deterioration events (CDEs) and contribute substantially to mortality. We assessed the association between suspected and laboratory-confirmed infection and mortality during CDEs. Methods: We conducted a secondary analysis of a prospective CDE registry (April 2019–December 2024) across 80 hospitals in Latin America and Spain. CDEs were defined as unplanned ICU transfer or delivery of ICU-level interventions on the ward. Events were classified as suspected or not suspected to be caused by infection; suspected infections were further categorized into those with and without laboratory confirmation. We compared patient-, event-, and hospital-level characteristics across groups. The primary outcome was CDE mortality. Mortality risk was analyzed using generalized estimating equations (Poisson, log link) with hospital clustering, adjusted for C-reactive protein, neutropenia severity, cancer type, and relapse/progression. Results: Among 3,859 CDEs, infection was suspected as the cause of 2,873 (74.4%); of these, 1,296 (45.1%) had laboratory confirmation. Compared with no suspected infection, events with any suspected infection (confirmed or unconfirmed) was associated with higher mortality risk (aRR: 1.18; 95% CI: 1.02–1.37; p<0.05). Laboratory-confirmed infection further increased mortality risk (aRR: 1.30; 95% CI: 1.12–1.52; p=0.001). Bacteremia (aRR: 1.33, 95% CI: 1.15-1.54, p<0.001), fungemia (aRR: 1.54, 95% CI: 1.27-1.87, p<0.001), systemic viral (aRR: 1.52, 95% CI: 1.19-1.94, p=0.001), and polymicrobial bloodstream infections (aRR: 1.59, 95% CI: 1.31-1.94, p<0.001) independently increased mortality risk. Among children with suspected and laboratory-confirmed infections, those at publicly funded hospitals and in lower-middle and upper-middle income countries had higher mortality risk. Conclusions: Most CDEs in pediatric oncology were infection-related and confirmed infections substantially increased mortality risk. Strengthening infection prevention, early recognition, diagnostics, and timely treatment is critical to improving survival.
- Open Access
Changes in the Epidemiology of Pneumonia in Children Younger than 14 Years Old During and After the COVID-19 Pandemic in Mexico, a National Multicenter Study
Background: In 2019, pneumonia caused 740,180 deaths in children under five years of age, representing 22% of global mortality in this age group. During the COVID-19 pandemic, public health interventions markedly reduced the circulation of most respiratory viruses other than SARS-CoV-2, leading to significant post-pandemic shifts in respiratory pathogen epidemiology. This study aimed to characterize the epidemiology, clinical features, and risk factors associated with respiratory viruses and bacteria causing pneumonia in Mexican children during the late pandemic and post pandemic periods. Methods: Children younger than 14 years with pneumonia were recruited from seven hospitals in Mexico. Demographic and clinical data were collected, and nasopharyngeal swabs were analyzed using a multiplex PCR panel detecting 19 viruses and 7 bacteria. Univariate, bivariate, and logistic regression analyses were performed (SPSS v25). Results: A total of 1715 children were included: 704 during the pandemic (2021–2023) and 1011 post-pandemic (2023–2025). Co-infections (72% vs. 65%, p < 0.001), virus–virus co-infections (25% vs. 11%, p < 0.001), and single viral infections (20% vs. 15%, p = 0.007) were more frequent during the pandemic. Pathogen detection was high in both periods, though negative samples increased post-pandemic (5.4% vs. 15%, p < 0.001). During the pandemic, the 5 most frequently detected pathogens were rhinovirus (66%), RSV A and B (38%), Streptococcus pneumoniae (30%), Haemophilus influenzae (28%), human metapneumovirus (13%). In the post-pandemic period, the 5 most frequently detected pathogens were rhinovirus (52%), Haemophilus influenzae (36%), Streptococcus pneumoniae (35%), RSV A and B (28%), metapneumovirus (11%). Rhinovirus and RSV predominated during the pandemic, whereas Haemophilus influenzae, Streptococcus pneumoniae, parainfluenza viruses, Bordetella pertussis, and Mycoplasma pneumoniae significantly increased post-pandemic. Conclusions: Pediatric pneumonia epidemiology shifted from a predominantly viral profile during the pandemic to increased bacterial detections and virus–bacteria co-infections post-pandemic, alongside re-emergence of typical RSV and influenza seasonality. Higher mean age and rhinovirus as the most frequent pathogen persist after the pandemic. Sustained molecular surveillance and reinforced vaccination programs remain essential in the post-pandemic era.
Open AccessChanges in the Epidemiology of Pneumonia in Children Younger than 14 Years Old During and After the COVID-19 Pandemic in Mexico, a National Multicenter Study
Background: In 2019, pneumonia caused 740,180 deaths in children under five years of age, representing 22% of global mortality in this age group. During the COVID-19 pandemic, public health interventions markedly reduced the circulation of most respiratory viruses other than SARS-CoV-2, leading to significant post-pandemic shifts in respiratory pathogen epidemiology. This study aimed to characterize the epidemiology, clinical features, and risk factors associated with respiratory viruses and bacteria causing pneumonia in Mexican children during the late pandemic and post pandemic periods. Methods: Children younger than 14 years with pneumonia were recruited from seven hospitals in Mexico. Demographic and clinical data were collected, and nasopharyngeal swabs were analyzed using a multiplex PCR panel detecting 19 viruses and 7 bacteria. Univariate, bivariate, and logistic regression analyses were performed (SPSS v25). Results: A total of 1715 children were included: 704 during the pandemic (2021–2023) and 1011 post-pandemic (2023–2025). Co-infections (72% vs. 65%, p < 0.001), virus–virus co-infections (25% vs. 11%, p < 0.001), and single viral infections (20% vs. 15%, p = 0.007) were more frequent during the pandemic. Pathogen detection was high in both periods, though negative samples increased post-pandemic (5.4% vs. 15%, p < 0.001). During the pandemic, the 5 most frequently detected pathogens were rhinovirus (66%), RSV A and B (38%), Streptococcus pneumoniae (30%), Haemophilus influenzae (28%), human metapneumovirus (13%). In the post-pandemic period, the 5 most frequently detected pathogens were rhinovirus (52%), Haemophilus influenzae (36%), Streptococcus pneumoniae (35%), RSV A and B (28%), metapneumovirus (11%). Rhinovirus and RSV predominated during the pandemic, whereas Haemophilus influenzae, Streptococcus pneumoniae, parainfluenza viruses, Bordetella pertussis, and Mycoplasma pneumoniae significantly increased post-pandemic. Conclusions: Pediatric pneumonia epidemiology shifted from a predominantly viral profile during the pandemic to increased bacterial detections and virus–bacteria co-infections post-pandemic, alongside re-emergence of typical RSV and influenza seasonality. Higher mean age and rhinovirus as the most frequent pathogen persist after the pandemic. Sustained molecular surveillance and reinforced vaccination programs remain essential in the post-pandemic era.
- Open Access
Genotypic Diversity of Human Rhinovirus in Children with Pneumonia Before and During the COVID-19 Pandemic in Mexico
Human rhinovirus (HRV) is one of the most common viral causes of respiratory tract infections worldwide. The COVID-19 pandemic and non-pharmaceutical interventions significantly altered the epidemiology of respiratory viruses. This study compared HRV genotypic diversity in Mexican children with pneumonia before and during the pandemic. A total of 1983 children with pneumonia were included: 1404 pre-pandemic (2010–2013) and 579 pandemic (2021–2023). Multiplex RT-PCR was used for HRV detection. Genotyping was conducted on 136 samples with Ct < 30 by sequencing the VP4/VP2 region. Species and genotype assignments were validated using BLAST and maximum-likelihood phylogenetic analysis (MEGA XII). HRV positivity increased from 16% (233/1404) before the pandemic to 60.4% (350/579) during the pandemic period. HRV-A and HRV-C predominated in both periods; HRV-C infection was significantly associated with severe pneumonia in the pre-pandemic period (OR 3.520; p = 0.012), but this association was not observed during the pandemic. A total of 72 genotypes were identified without a dominant type in either period. HRV circulation patterns shifted in the context of the COVID-19 pandemic, with a marked increase in prevalence. The high genotypic diversity observed across both periods underscores the importance of continuous molecular surveillance to better understand HRV circulation and its clinical relevance.
Open AccessGenotypic Diversity of Human Rhinovirus in Children with Pneumonia Before and During the COVID-19 Pandemic in Mexico
Human rhinovirus (HRV) is one of the most common viral causes of respiratory tract infections worldwide. The COVID-19 pandemic and non-pharmaceutical interventions significantly altered the epidemiology of respiratory viruses. This study compared HRV genotypic diversity in Mexican children with pneumonia before and during the pandemic. A total of 1983 children with pneumonia were included: 1404 pre-pandemic (2010–2013) and 579 pandemic (2021–2023). Multiplex RT-PCR was used for HRV detection. Genotyping was conducted on 136 samples with Ct < 30 by sequencing the VP4/VP2 region. Species and genotype assignments were validated using BLAST and maximum-likelihood phylogenetic analysis (MEGA XII). HRV positivity increased from 16% (233/1404) before the pandemic to 60.4% (350/579) during the pandemic period. HRV-A and HRV-C predominated in both periods; HRV-C infection was significantly associated with severe pneumonia in the pre-pandemic period (OR 3.520; p = 0.012), but this association was not observed during the pandemic. A total of 72 genotypes were identified without a dominant type in either period. HRV circulation patterns shifted in the context of the COVID-19 pandemic, with a marked increase in prevalence. The high genotypic diversity observed across both periods underscores the importance of continuous molecular surveillance to better understand HRV circulation and its clinical relevance.
- Open Access
- 8 November 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (6) , 139
Epidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19 Pandemic
Background/Objectives: Respiratory syncytial virus (RSV) significantly affects young children. In 2020, at the beginning of the COVID-19 pandemic, widespread public health measures temporarily interrupted RSV transmission. However, by mid-2021, an atypical resurgence of RSV was observed. The objective of this study was to compare the clinical and epidemiological characteristics of RSV infections in children before and during the second half of the SARS-CoV-2 pandemic in Mexico. Methods: A comparative ambispective longitudinal epidemiological study was conducted using two distinct cohorts: one from 2010 to 2013 and another from 2021 to 2023. The study included children under five years of age diagnosed with RSV-related pneumonia. Statistical analyses included Student’s t-tests, chi-square tests, and logistic regression to identify risk factors associated with severe pneumonia. Incidence density was calculated as the number of RSV-positive pneumonia cases per 10 new pneumonia admissions per month. Results: The mean age of affected children increased from 10 to 15 months. RSV activity began earlier in 2021, emerging during the summer months, and showed a higher incidence than in previous seasons. RSV type B was significantly more common during the pandemic period (58.5% vs. 3.8%), and the proportion of co-infections also increased (60% vs. 39%), indicating a change in the viral landscape. Conclusions: These findings indicate a shift in RSV seasonality toward summer and autumn, increased case incidence, and infections in older children. These observations underscore the need for ongoing surveillance to better understand evolving RSV patterns, especially in the context of complex public health scenarios like the COVID-19 pandemic.
- 8 November 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (6) , 139
Open AccessEpidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19 Pandemic
Background/Objectives: Respiratory syncytial virus (RSV) significantly affects young children. In 2020, at the beginning of the COVID-19 pandemic, widespread public health measures temporarily interrupted RSV transmission. However, by mid-2021, an atypical resurgence of RSV was observed. The objective of this study was to compare the clinical and epidemiological characteristics of RSV infections in children before and during the second half of the SARS-CoV-2 pandemic in Mexico. Methods: A comparative ambispective longitudinal epidemiological study was conducted using two distinct cohorts: one from 2010 to 2013 and another from 2021 to 2023. The study included children under five years of age diagnosed with RSV-related pneumonia. Statistical analyses included Student’s t-tests, chi-square tests, and logistic regression to identify risk factors associated with severe pneumonia. Incidence density was calculated as the number of RSV-positive pneumonia cases per 10 new pneumonia admissions per month. Results: The mean age of affected children increased from 10 to 15 months. RSV activity began earlier in 2021, emerging during the summer months, and showed a higher incidence than in previous seasons. RSV type B was significantly more common during the pandemic period (58.5% vs. 3.8%), and the proportion of co-infections also increased (60% vs. 39%), indicating a change in the viral landscape. Conclusions: These findings indicate a shift in RSV seasonality toward summer and autumn, increased case incidence, and infections in older children. These observations underscore the need for ongoing surveillance to better understand evolving RSV patterns, especially in the context of complex public health scenarios like the COVID-19 pandemic.
- Open Access
Circulation of RSV Subtypes A and B Among Mexican Children During the 2021–2022 and 2022–2023 Seasons
Respiratory syncytial virus (RSV) remains a leading cause of pneumonia in young children in Mexico and worldwide. To investigate RSV dynamics in Mexico, we conducted a multicenter study from August 2021 to July 2023 in six hospitals across five States, analyzing respiratory samples from children under five years with pneumonia. Multiplex RT-PCR identified 203 RSV-positive cases, of which 123 were RSV-B and 80 RSV-A. Interestingly, 77% of the collected samples showed evidence of coinfection with other respiratory pathogens, with rhinovirus, Haemophilus influenzae, and Streptococcus pneumoniae being the most common. Also, RSV-B dominated in 2021–2022, whereas RSV-A prevailed in 2022–2023, mirroring trends observed in the United States. Sequences of the genes encoding G and F proteins showed that RSV-A lineages were more diverse, with A.D.1, A.D.1.8, and A.D.5.2 being frequently detected. In contrast, nearly all RSV-B sequences belonged to lineage B.D.E.1. Finally, ancestral state inference suggests repeated introductions from the USA and other North American countries, with limited evidence of sustained local circulation. These findings show different trends in RSV circulation between two consecutive seasons and the importance of genomic surveillance to monitor RSV diversity, evaluate vaccine impact, and inform public health strategies in Mexico’s evolving post-pandemic respiratory virus landscape.
Open AccessCirculation of RSV Subtypes A and B Among Mexican Children During the 2021–2022 and 2022–2023 Seasons
Respiratory syncytial virus (RSV) remains a leading cause of pneumonia in young children in Mexico and worldwide. To investigate RSV dynamics in Mexico, we conducted a multicenter study from August 2021 to July 2023 in six hospitals across five States, analyzing respiratory samples from children under five years with pneumonia. Multiplex RT-PCR identified 203 RSV-positive cases, of which 123 were RSV-B and 80 RSV-A. Interestingly, 77% of the collected samples showed evidence of coinfection with other respiratory pathogens, with rhinovirus, Haemophilus influenzae, and Streptococcus pneumoniae being the most common. Also, RSV-B dominated in 2021–2022, whereas RSV-A prevailed in 2022–2023, mirroring trends observed in the United States. Sequences of the genes encoding G and F proteins showed that RSV-A lineages were more diverse, with A.D.1, A.D.1.8, and A.D.5.2 being frequently detected. In contrast, nearly all RSV-B sequences belonged to lineage B.D.E.1. Finally, ancestral state inference suggests repeated introductions from the USA and other North American countries, with limited evidence of sustained local circulation. These findings show different trends in RSV circulation between two consecutive seasons and the importance of genomic surveillance to monitor RSV diversity, evaluate vaccine impact, and inform public health strategies in Mexico’s evolving post-pandemic respiratory virus landscape.
- Open Access
Genotypic Characterization of Human Respiratory Syncytial Viruses Detected in Mexico Between 2021 and 2024
Human respiratory syncytial virus (HRSV) is a leading cause of severe respiratory infections among children, older adults, and immunocompromised individuals. The COVID-19 pandemic and the non-pharmacological interventions to mitigate it resulted in significant changes in HRSV epidemiology and seasonality patterns. Worldwide, there was a considerable reduction in the number of HRSV infections during that period, and the impact of those changes on genotype distribution is still not fully understood. In this work, we analyzed the genotypic characteristics of HRSV strains detected between 2021 and 2024 in Mexico with the aim of identifying changes in circulating lineages. HRSV positive samples collected in five states in Mexico were used. The complete viral attachment glycoprotein gene was sequenced, and phylogenetic inference was performed using datasets including all sequences available at GenBank and GISAID until 30 June 2024. We obtained 114 HRSV sequences (63.2% HRSV-A and 36.8% HRSV-B); 19 were from the 2021–2022 season, 53 from 2022–2023, and 42 from 2023–2024. All HRSV-A sequences clustered with sequences from other countries within A.D lineages, including A.D.1, A.D.3, A.D.5.1, and A.D.5.2 lineages. All HRSV-B sequences clustered in the B.D.E.1 lineage with sequences collected between 2020 and 2024. In conclusion, the characterization of HRSV viruses circulating in Mexico during and after the SARS-CoV-2 pandemic and comparison to all available sequences reported to date corroborates that, on a global scale, HRSV-A viruses of several A.D lineages circulate simultaneously, while HRSV-B viruses are restricted to the B.D.E.1 lineage.
Open AccessGenotypic Characterization of Human Respiratory Syncytial Viruses Detected in Mexico Between 2021 and 2024
Human respiratory syncytial virus (HRSV) is a leading cause of severe respiratory infections among children, older adults, and immunocompromised individuals. The COVID-19 pandemic and the non-pharmacological interventions to mitigate it resulted in significant changes in HRSV epidemiology and seasonality patterns. Worldwide, there was a considerable reduction in the number of HRSV infections during that period, and the impact of those changes on genotype distribution is still not fully understood. In this work, we analyzed the genotypic characteristics of HRSV strains detected between 2021 and 2024 in Mexico with the aim of identifying changes in circulating lineages. HRSV positive samples collected in five states in Mexico were used. The complete viral attachment glycoprotein gene was sequenced, and phylogenetic inference was performed using datasets including all sequences available at GenBank and GISAID until 30 June 2024. We obtained 114 HRSV sequences (63.2% HRSV-A and 36.8% HRSV-B); 19 were from the 2021–2022 season, 53 from 2022–2023, and 42 from 2023–2024. All HRSV-A sequences clustered with sequences from other countries within A.D lineages, including A.D.1, A.D.3, A.D.5.1, and A.D.5.2 lineages. All HRSV-B sequences clustered in the B.D.E.1 lineage with sequences collected between 2020 and 2024. In conclusion, the characterization of HRSV viruses circulating in Mexico during and after the SARS-CoV-2 pandemic and comparison to all available sequences reported to date corroborates that, on a global scale, HRSV-A viruses of several A.D lineages circulate simultaneously, while HRSV-B viruses are restricted to the B.D.E.1 lineage.
- Open Access
- 1 January 2024
- Published by Wiley in Advances in Virology
- Vol. 2024 (1) , 8841838
Increased Incidence of Rhinovirus Pneumonia in Children During the COVID‐19 Pandemic in Mexico
Background: Human rhinovirus (HRV), traditionally recognized as the primary etiological agent of the common cold, has become the second most important viral agent in bronchopulmonary conditions, such as pneumonia and asthma exacerbations. During the COVID‐19 pandemic, several viruses exhibited changes in their epidemiological behavior. This study aims to evaluate the clinical and epidemiological characteristics of children with HRV pneumonia before and during the pandemic in Mexico.Methods: A comparative ambispective longitudinal epidemiological study of two cohorts (prepandemic and pandemic periods) was carried out. Two databases were compared: one from 2010 to 2013 and the other from 2021 to 2023. Children under 5 years of age diagnosed with HRV pneumonia were included. Student’s t‐test, χ2 tests, and logistic regression were used to assess risk factors associated with severe pneumonia. Incidence density was calculated as HRV cases per 10 new cases of pneumonia per month for each year.Results: During the pandemic, the age of presentation shifted from 5 months to 16 months. There was a higher incidence of HRV pneumonia in children during the pandemic, particularly in the second half of 2021, with a peak in July and August. In addition, there was an increase in severity (53% vs. 63%, p = 0.006) and coinfections (51.3% vs. 76% p < 0.001). A higher prevalence of all risk factors was observed in the second cohort.Conclusions: During the pandemic, a shift toward older age, a higher percentage of coinfections, and increased severity associated to HRV pneumonia were observed. These findings highlight the need for the development and implementation of targeted prevention and treatment measures for HRV.
- 1 January 2024
- Published by Wiley in Advances in Virology
- Vol. 2024 (1) , 8841838
Open AccessIncreased Incidence of Rhinovirus Pneumonia in Children During the COVID‐19 Pandemic in Mexico
Background: Human rhinovirus (HRV), traditionally recognized as the primary etiological agent of the common cold, has become the second most important viral agent in bronchopulmonary conditions, such as pneumonia and asthma exacerbations. During the COVID‐19 pandemic, several viruses exhibited changes in their epidemiological behavior. This study aims to evaluate the clinical and epidemiological characteristics of children with HRV pneumonia before and during the pandemic in Mexico.Methods: A comparative ambispective longitudinal epidemiological study of two cohorts (prepandemic and pandemic periods) was carried out. Two databases were compared: one from 2010 to 2013 and the other from 2021 to 2023. Children under 5 years of age diagnosed with HRV pneumonia were included. Student’s t‐test, χ2 tests, and logistic regression were used to assess risk factors associated with severe pneumonia. Incidence density was calculated as HRV cases per 10 new cases of pneumonia per month for each year.Results: During the pandemic, the age of presentation shifted from 5 months to 16 months. There was a higher incidence of HRV pneumonia in children during the pandemic, particularly in the second half of 2021, with a peak in July and August. In addition, there was an increase in severity (53% vs. 63%, p = 0.006) and coinfections (51.3% vs. 76% p < 0.001). A higher prevalence of all risk factors was observed in the second cohort.Conclusions: During the pandemic, a shift toward older age, a higher percentage of coinfections, and increased severity associated to HRV pneumonia were observed. These findings highlight the need for the development and implementation of targeted prevention and treatment measures for HRV.
- 22 June 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (10) , e382-e384
Clinical and Epidemiologic Characteristics of Infants Hospitalized with Respiratory Syncytial Virus Infection During the 2022–2023 Season in Mexico
In 2022, several countries reported an increase in respiratory syncytial virus (RSV) infections. We assessed the clinical characteristics and outcomes of infants hospitalized with RSV and compared them with infants hospitalized between 2009 and 2015. No significant differences in underlying disorders, intensive care unit admission rates and mortality were observed suggesting currently circulating RSV strains do not show heightened virulence.
- 22 June 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (10) , e382-e384
Clinical and Epidemiologic Characteristics of Infants Hospitalized with Respiratory Syncytial Virus Infection During the 2022–2023 Season in Mexico
In 2022, several countries reported an increase in respiratory syncytial virus (RSV) infections. We assessed the clinical characteristics and outcomes of infants hospitalized with RSV and compared them with infants hospitalized between 2009 and 2015. No significant differences in underlying disorders, intensive care unit admission rates and mortality were observed suggesting currently circulating RSV strains do not show heightened virulence.